AP3360A - Pyrazole compounds as CRTH2 antagonists - Google Patents

Pyrazole compounds as CRTH2 antagonists

Info

Publication number
AP3360A
AP3360A AP2012006313A AP2012006313A AP3360A AP 3360 A AP3360 A AP 3360A AP 2012006313 A AP2012006313 A AP 2012006313A AP 2012006313 A AP2012006313 A AP 2012006313A AP 3360 A AP3360 A AP 3360A
Authority
AP
ARIPO
Prior art keywords
pyrazole compounds
crth2 antagonists
crth2
antagonists
pyrazole
Prior art date
Application number
AP2012006313A
Other languages
English (en)
Other versions
AP2012006313A0 (en
Inventor
Thorsten Oost
Wolfgang Rist
Dominic Martyres
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42112128&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3360(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AP2012006313A0 publication Critical patent/AP2012006313A0/xx
Application granted granted Critical
Publication of AP3360A publication Critical patent/AP3360A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
AP2012006313A 2010-01-27 2011-01-24 Pyrazole compounds as CRTH2 antagonists AP3360A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10151785 2010-01-27
PCT/EP2011/050910 WO2011092140A1 (en) 2010-01-27 2011-01-24 Pyrazole compounds as crth2 antagonists

Publications (2)

Publication Number Publication Date
AP2012006313A0 AP2012006313A0 (en) 2012-06-30
AP3360A true AP3360A (en) 2015-07-31

Family

ID=42112128

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006313A AP3360A (en) 2010-01-27 2011-01-24 Pyrazole compounds as CRTH2 antagonists

Country Status (37)

Country Link
US (1) US8791272B2 (ko)
EP (1) EP2528901B9 (ko)
JP (1) JP5658284B2 (ko)
KR (2) KR101906791B1 (ko)
CN (3) CN102884051B (ko)
AP (1) AP3360A (ko)
AR (1) AR080032A1 (ko)
AU (1) AU2011209286B2 (ko)
BR (1) BR112012018695A2 (ko)
CA (1) CA2788224C (ko)
CL (1) CL2012001836A1 (ko)
CO (1) CO6511272A2 (ko)
CY (1) CY1116641T1 (ko)
DK (1) DK2528901T3 (ko)
EA (1) EA022280B1 (ko)
ES (1) ES2545865T3 (ko)
GE (1) GEP20146177B (ko)
HR (1) HRP20150898T1 (ko)
HU (1) HUE025318T2 (ko)
IL (1) IL220208A (ko)
MA (1) MA33937B1 (ko)
MX (1) MX353000B (ko)
MY (1) MY160036A (ko)
NZ (1) NZ600637A (ko)
PE (1) PE20121519A1 (ko)
PH (1) PH12012501536A1 (ko)
PL (1) PL2528901T3 (ko)
PT (1) PT2528901E (ko)
RS (1) RS54176B1 (ko)
SG (1) SG182684A1 (ko)
SI (1) SI2528901T1 (ko)
TN (1) TN2012000371A1 (ko)
TW (1) TWI499416B (ko)
UA (1) UA110025C2 (ko)
UY (1) UY33201A (ko)
WO (1) WO2011092140A1 (ko)
ZA (1) ZA201204335B (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY160036A (en) 2010-01-27 2017-02-15 Boehringer Ingelheim Int Pyrazole compounds as crth2 antagonists
JP2014504280A (ja) * 2010-11-24 2014-02-20 アラーガン インコーポレイテッド Ｓ１ｐ受容体調節剤
TWI527809B (zh) * 2011-01-24 2016-04-01 百靈佳殷格翰國際股份有限公司 作為ｃｒｔｈ２拮抗劑之吡唑化合物
CN103113303A (zh) * 2011-11-16 2013-05-22 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的氮杂环化合物
PL2781508T3 (pl) 2011-11-17 2019-06-28 Kbp Biosciences Co., Ltd. Związki pierścieniowe o układzie skondensowanych pierścieni zawierające azot do zastosowania jako antagonisty CRTH2
WO2013101598A1 (en) * 2011-12-27 2013-07-04 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
JP6182593B2 (ja) 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
US20140148484A1 (en) * 2012-11-23 2014-05-29 Boehringer Ingelheim International Gmbh Pyrazole compounds for treating hairloss
WO2014138979A1 (en) 2013-03-13 2014-09-18 Canadian Blood Services Pyrazole derivatives and their uses thereof
CN103265535B (zh) * 2013-05-14 2015-06-17 浙江医药高等专科学校 抗肿瘤化合物、其制备方法和用途
CN103265537B (zh) * 2013-05-14 2015-05-27 浙江医药高等专科学校 抗肿瘤化合物、其制备方法和用途
MX389591B (es) 2014-08-29 2025-03-20 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
TWI903299B (zh) 2018-03-08 2025-11-01 美商英塞特公司 作為PI3K-γ抑制劑之胺基吡嗪二醇化合物
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
JP2022536081A (ja) 2019-06-06 2022-08-12 ビーエーエスエフ ソシエタス・ヨーロピア 殺菌ｎ－（ピリド－３－イル）カルボキサミド
WO2021063735A1 (en) 2019-10-02 2021-04-08 Basf Se New bicyclic pyridine derivatives
WO2025009852A1 (ko) * 2023-07-03 2025-01-09 주식회사 이노보테라퓨틱스 신규한 피라졸 유도체 및 이의 용도
CN117088785B (zh) * 2023-08-18 2026-01-06 江西金丰药业有限公司 一种4-氨基-2-甲基苯甲酸的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038325A1 (en) * 1999-11-10 2001-05-31 Takeda Chemical Industries, Ltd. 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
US20100016368A1 (en) * 2008-07-15 2010-01-21 Li Chen Aminotetrahydroindazoloacetic acids

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4828914B1 (ko) * 1969-04-11 1973-09-05
US4146721A (en) * 1969-09-12 1979-03-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyrazol-4-acetic acid compounds
BE759032A (fr) * 1969-11-17 1971-04-30 Takeda Chemical Industries Ltd Acide 3,5-diphenyl-4-pyrazole acetique ou ses derives 1-substitues ou leurs esters
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
JP2002348281A (ja) * 2001-03-23 2002-12-04 Takeda Chem Ind Ltd ５員複素環アルカン酸誘導体
JP2003073377A (ja) * 2001-06-20 2003-03-12 Takeda Chem Ind Ltd ５員複素環誘導体
IL161009A0 (en) * 2001-09-25 2004-08-31 Pharmacia Corp Process for making substituted pyrazoles
MXPA05003456A (es) * 2002-10-04 2005-07-05 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
ATE316077T1 (de) 2003-04-25 2006-02-15 Actimis Pharmaceuticals Inc Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten
WO2005040128A1 (en) 2003-10-24 2005-05-06 Glaxo Group Limited Heterocyclyl compounds
GB0525141D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525144D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
JP2009539795A (ja) 2006-06-06 2009-11-19 グラクソ グループ リミテッド 疼痛、炎症および神経変性の治療のためのｐ２ｘ７アンタゴニストとしてのｎ−（フェニルメチル）−２−（１ｈ−ピラゾール−４−イル）アセトアミド誘導体
US20110046137A1 (en) 2007-05-10 2011-02-24 Glaxo Group Limited Pyrazole Derivatives as P2X7 Modulators
PT2205569E (pt) 2007-09-25 2012-05-25 Actimis Pharmaceuticals Inc Alquiltiopirimidinas como antagonistas de crth2
KR20100061746A (ko) 2007-09-25 2010-06-08 액티미스 파마수티컬스 인코포레이티드 Ｃｒｔｈ２ 길항제로서의 ２－ｓ－벤질 치환된 피리미딘
GB0719521D0 (en) * 2007-10-05 2007-11-14 Argenta Discovery Ltd Compounds
US8293917B2 (en) * 2008-05-06 2012-10-23 Boehringer Ingelheim International Gmbh Pyrazole compounds as CCR1 antagonists
MY160036A (en) 2010-01-27 2017-02-15 Boehringer Ingelheim Int Pyrazole compounds as crth2 antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038325A1 (en) * 1999-11-10 2001-05-31 Takeda Chemical Industries, Ltd. 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
US20100016368A1 (en) * 2008-07-15 2010-01-21 Li Chen Aminotetrahydroindazoloacetic acids

Also Published As

Publication number Publication date
UY33201A (es) 2011-08-31
AU2011209286B2 (en) 2016-02-11
GEP20146177B (en) 2014-10-10
SI2528901T1 (sl) 2015-10-30
EP2528901B9 (en) 2017-01-25
EP2528901B1 (en) 2015-05-27
CY1116641T1 (el) 2017-03-15
TN2012000371A1 (en) 2014-01-30
KR101906791B1 (ko) 2018-10-11
CA2788224C (en) 2015-07-21
PE20121519A1 (es) 2012-12-02
AP2012006313A0 (en) 2012-06-30
HK1176062A1 (zh) 2013-07-19
PT2528901E (pt) 2015-10-13
CO6511272A2 (es) 2012-08-31
WO2011092140A1 (en) 2011-08-04
JP5658284B2 (ja) 2015-01-21
MX2012008361A (es) 2012-08-08
ZA201204335B (en) 2019-08-28
EP2528901A1 (en) 2012-12-05
DK2528901T3 (en) 2015-08-17
US20120028938A1 (en) 2012-02-02
US8791272B2 (en) 2014-07-29
CA2788224A1 (en) 2011-08-04
JP2013518074A (ja) 2013-05-20
CL2012001836A1 (es) 2012-11-23
AR080032A1 (es) 2012-03-07
ES2545865T3 (es) 2015-09-16
TWI499416B (zh) 2015-09-11
MY160036A (en) 2017-02-15
KR20120117841A (ko) 2012-10-24
TW201138769A (en) 2011-11-16
HUE025318T2 (en) 2016-02-29
IL220208A (en) 2016-11-30
HRP20150898T1 (hr) 2015-10-09
KR20170142217A (ko) 2017-12-27
MA33937B1 (fr) 2013-01-02
NZ600637A (en) 2014-07-25
PH12012501536A1 (en) 2012-10-22
EA022280B1 (ru) 2015-12-30
CN104829535A (zh) 2015-08-12
BR112012018695A2 (pt) 2016-04-12
KR101812000B1 (ko) 2017-12-26
CN102884051B (zh) 2015-09-16
PL2528901T3 (pl) 2015-11-30
IL220208A0 (en) 2012-07-31
SG182684A1 (en) 2012-08-30
CN108383789A (zh) 2018-08-10
MX353000B (es) 2017-12-15
UA110025C2 (xx) 2015-11-10
CN102884051A (zh) 2013-01-16
AU2011209286A1 (en) 2012-07-05
RS54176B1 (sr) 2015-12-31
EA201201050A1 (ru) 2013-02-28

Similar Documents

Publication Publication Date Title
AP3360A (en) Pyrazole compounds as CRTH2 antagonists
AP3391A (en) 2-Amino-4-arylthiazole compounds as TROA1 antagonists
IL225770A0 (en) Heterocyclic compounds
IL221442A0 (en) Heterocyclic compound
GB201007286D0 (en) New compounds
GB201020179D0 (en) New compounds
AP2012006641A0 (en) New compounds
PL2521450T3 (pl) Grzybobójcze związki heterocykliczne
ZA201300950B (en) Heterocyclic compound
PT2648516T (pt) Compostos de piridinona-piridinilo substituídos
ZA201304282B (en) Pyrazole derivative
AP3218A (en) Compounds as bradykinin B1 antagonists
IL226920A (en) Pyrazole compounds as antagonists of crth2
PL2634171T3 (pl) 23-ynowa pochodna witaminy D3
GB201021416D0 (en) Novel heterocyclic compounds
GB201009514D0 (en) Novel heterocyclic compounds
GB201016221D0 (en) New compounds
GB201012899D0 (en) New compounds
GB201004307D0 (en) New compounds